INSIGHTS ON CLINICAL TRIAL PARTNERING

• An Introduction To One Home for Sites™

  This on-demand webinar provides a thorough overview of why IQVIA Technologies is building One Home for Sites, how it works, and who should participate.

• Strategic Considerations For Oncology Trials In A Competitive Landscape

  By combining strategic foresight with hands-on support, the right partner accelerates oncology trial delivery and broadens access to promising therapies.

• Elevating The Site Voice

  A decentralized trial can be daunting for sites, but Medidata offers solutions to help site staff, sponsors, and patients move smoothly through the clinical trial process.

• Top 5 Challenges In Psoriasis Trials (And How To Overcome Them)

  Psoriasis trials face recruitment, endpoint, regulatory, and operational challenges. Identifying common hurdles early helps sponsors streamline processes, avoid setbacks, and prevent costly delays.

• Addressing Site Selection Challenges In DMD Gene Therapy Studies

  1/14/2025

  Effective site selection is critical for the success of DMD gene therapy trials. This study details innovative methodologies employed to streamline and improve site identification.

• 10 Roadblocks To Traditional Vendor Selection And How ClinAI Solves Them

  7/1/2025

  Vendor selection in clinical trials is a pivotal process. Explore ten widespread inefficiencies in the current approach and how you can resolve them.

• Australia's Edge In Oncology And Nuclear Medicine Trials

  11/21/2025

  Discover how we leverage Australia’s world-class clinical infrastructure, streamlined regulatory environment, and early-phase expertise to accelerate oncology and nuclear medicine trials.

• Taming The Complex Clinical-Trial Ecosystem

  4/9/2025

  To navigate the growing number of vendor portals required for clinical trials, sites are seeking a vendor- and sponsor-agnostic solution to enable single sign-on and study organization.

• Key Strategies For Clinical Development In Rare Cancers

  2/11/2025

  Successful execution of rare cancer clinical trials requires strategic patient recruitment, innovative trial design, and specialized expertise from Oncology CROs.